Integrated genetic and pharmacologic interrogation of rare cancers

Identifying therapeutic targets in rare cancers remains challenging due to the paucity of established models to perform preclinical studies. As a proof-of-concept, we developed a patient-derived cancer cell line, CLF-PED-015-T, from a paediatric patient with a rare undifferentiated sarcoma. Here, we...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nat Commun
Autori principali: Hong, Andrew L., Tseng, Yuen-Yi, Cowley, Glenn S., Jonas, Oliver, Cheah, Jaime H., Kynnap, Bryan D., Doshi, Mihir B., Oh, Coyin, Meyer, Stephanie C., Church, Alanna J., Gill, Shubhroz, Bielski, Craig M., Keskula, Paula, Imamovic, Alma, Howell, Sara, Kryukov, Gregory V., Clemons, Paul A., Tsherniak, Aviad, Vazquez, Francisca, Crompton, Brian D., Shamji, Alykhan F., Rodriguez-Galindo, Carlos, Janeway, Katherine A., Roberts, Charles W. M., Stegmaier, Kimberly, van Hummelen, Paul, Cima, Michael J., Langer, Robert S., Garraway, Levi A., Schreiber, Stuart L., Root, David E., Hahn, William C., Boehm, Jesse S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4917959/
https://ncbi.nlm.nih.gov/pubmed/27329820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms11987
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi